Hypomethylating agents super-responders: challenging the dogma of long-term remission for acute myeloid leukemia

Ann Hematol. 2020 Jun;99(6):1411-1413. doi: 10.1007/s00277-020-04054-x. Epub 2020 May 6.

Authors

Joseph E Maakaron¹, Michael P Ozga², Gabriel N Mannis³, Will Pulley⁴, Matthew C Foster⁴, Joshua F Zeidner⁴, Alice S Mims²

Affiliations

¹ Division of Hematology, Oncology and Transplantation, University of Minnesota, 420 Delaware Street SE, MMC 480, Minneapolis, MN, 55455, USA. maaka001@umn.edu.
² The Ohio State University, Columbus, OH, USA.
³ Stanford School of Medicine, Stanford, CA, USA.
⁴ University of North Carolina, Chapel Hill, NC, USA.

PMID: 32377815
DOI: 10.1007/s00277-020-04054-x

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Aged
Antineoplastic Agents / therapeutic use*
Antineoplastic Combined Chemotherapy Protocols / adverse effects
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
DNA Methylation / drug effects*
Female
Humans
Leukemia, Myeloid, Acute / diagnosis
Leukemia, Myeloid, Acute / drug therapy*
Leukemia, Myeloid, Acute / genetics*
Male
Middle Aged
Molecular Diagnostic Techniques
Remission Induction
Treatment Outcome

Substances

Antineoplastic Agents